CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies--Immuno-oncology Advances Clinical Cancer Research.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26078428.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2558.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune escape is a hallmark of cancer development and metastasis. Regulatory T cells (Treg) are potent inhibitors of cancer immune surveillance but also prevent inflammation-driven tumorigenesis. The study by Wolf and colleagues, which was published in the February 2003 issue of Clinical Cancer Research, showed the expansion of Treg in solid cancer patients, providing a deeper understanding of cancer immune escape mechanisms that later set the stage for the development of scientific breakthroughs in cancer immunotherapy.
Medical subject headings
- Biomarkers, Tumor
- Forkhead Transcription Factors
- Ovarian Neoplasms
- T-Lymphocytes, Regulatory